Health Care · Pharmaceutical Preparations

PTCT PTC THERAPEUTICS, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 1070081168 filings
Russell 2000

PTCT at a glance

PTC THERAPEUTICS, INC. (PTCT, SEC CIK 1070081) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), PTC THERAPEUTICS, INC. (PTCT) reported revenue of $1.7 billion (up 114.5% from FY2024) and net income of $682.6 million. Diluted EPS was $7.78.
  • As of September 30, 2026, 34 institutional investment managers tracked by SignalX reported holding PTC THERAPEUTICS, INC. (PTCT) shares worth $2.6 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Boulding Mark Elliott on November 16, 2026 of 209 shares at $62.90 per share.
  • In the last 90 days, PTCT insiders reported 0 open-market purchases ($0) and 22 open-market sales ($5.9M) on Form 4, a net sale of $5.9M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$1.7B
+114.5% vs prior year
Insiders · 90 days
0 buys · 22 sells
Net −$5.9M
13F holders
34 funds
$2.6B · +0 vs prior quarter
Latest 8-K
Nov 3, 2026
Item 7.01 · Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Development and commercialization of treatments for rare diseases, with focus on sepiapterin programs from Censa acquisition
  • Strategic shift: Rights Satisfaction Agreement canceled contingent net sales payments, replaced with upfront $225.1M cash payment plus up to $500M milestone payments
  • Notable quantitative metric: $152.5M paid in development/regulatory milestones for sepiapterin since acquisition, including $57.5M in 2025 alone
  • Financial risk detail: Stressed need for substantial additional funding; reliance on equity, debt, collaborations, with potential dilution and restrictive covenants risks

Risk Factors

  • Regulatory risk U.S. FDA withdrawal of Translarna NDA resubmission for nmDMD after negative feedback in January 2026
  • Geopolitical exposure Sephience marketing approvals in U.S., EEA, Japan, Brazil with $111.2M 2025 net revenues, but country-specific pricing/licensing risks
  • Operational risk Emflaza U.S. orphan drug exclusivity expired Feb 2024 leading to increased generic competition impacting revenue
  • Competitive risk Emflaza facing generic competition post orphan drug exclusivity expiration, negatively affecting net product revenue
  • Financial risk Revenue concentration: Translarna net revenues $235.3M and Emflaza $146.4M in 2025, key products with regulatory uncertainties

Management Discussion & Analysis

  • Revenue impact: upfront $1.0B from Novartis Agreement in Jan 2025, with potential $1.9B milestones, 40% US profits share, tiered double-digit royalties ex-US
  • Operating cash flow $711.2M in 2025 vs $(107.7)M in 2024 and $(158.4)M in 2023, driven by Novartis upfront and clinical/commercial spend
  • Investing cash flow used $862.0M in 2025, primarily for product rights acquisition, marketable securities, and fixed assets purchases
  • Financing cash flow $331.1M in 2025 from Royalty Pharma fundings, option exercises, ESPP issuance, offset by contingent consideration and lease payments
  • Forward risks: ongoing costs from commercialization, clinical trials, regulatory requirements; milestone and royalty payment obligations; dependence on market access and pricing; 2026 Convertible Notes interest $4.3M annually

AI summary of the PTCT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $357.8M, up from $210.2M YoY, driven by Sephience and Evrysdi royalties
  • Sephience best performer: $181.9M sales vs $19.6M YoY; Emflaza worst, $25.1M vs $35.2M
  • Net loss $0.1M implied by reported data, versus $0.1M net income YoY; no margin percentages disclosed
  • Cash, equivalents and marketable securities $2.13B; operating cash flow $44.8M vs $745.5M
  • $535.4M convertible-note proceeds, $328.8M used for 2026 note repurchases; headwinds from Emflaza generics and Translarna access risks

Risk Factors

  • New regulatory risk: ST-920 acquisition adds FDA accelerated-approval uncertainty, with rolling BLA completion expected in fourth quarter 2026
  • Most material update: Translarna U.S. development discontinued after NDA withdrawal in February 2026, while EEA authorization remains affected by the EC negative opinion
  • Regulatory compliance risk: vatiquinone requires an additional controlled study after FDA’s August 2025 complete response letter
  • Operational risk: three distributors each exceeded the undisclosed concentration threshold for net product sales in 2026
  • Financial risk: $550.0 million 2031 Convertible Notes mature June 15, 2031, alongside $2,305.6 million royalty-sale liability carrying an 11.0% effective rate

AI summary of the PTCT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 3, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Board-authorized share repurchase program announced November 3, 2026
  • Potential shareholder return support and reduced share count, with program terms in Exhibit 99.1

Item 8.01: Other Events

  • Board-authorized share repurchase program of up to $500.0 million
  • Potentially supports per-share value and signals management confidence in the company’s valuation

Item EX-99.1: Item EX-99.1

  • Board authorization for up to $500 million in common-stock repurchases, subject to market conditions
  • Repurchases may include open-market purchases, trading plans, privately negotiated transactions and accelerated share repurchases
Filed Oct 29, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $357.6M, up from $201.7M, led by Sephience product revenue of $181.9M
  • Full-year 2026 revenue guidance raised to $1.29B-$1.32B, product revenue to $960M-$990M

Item EX-99.2: Item EX-99.2

  • 2026 product revenue guidance: $1.29-$1.32B, representing 64%-69% YoY growth
  • Total revenue guidance: $960-$990M, with non-GAAP OpEx of $680-$720M

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1

Item 7.01: Regulation FD Disclosure

  • Conference call scheduled for October 29, 2026 at 4:30 p.m. Eastern
  • Management to review quarter ended September 30, 2026 financial results
Filed Sep 21, 2026Full analysis →

Item 8.01: Other Events

  • Acquisition completed September 21, 2026, expanding PTC Therapeutics’ development portfolio
  • Rolling U.S. BLA submission for ST-920 expected in fourth quarter 2026

Item EX-99.1: Item EX-99.1

  • Acquisition of ST-920 from Sangamo completed, adding a BLA-stage Fabry disease gene therapy to PTC’s rare-disease portfolio
  • Rolling FDA BLA submission targeting completion in Q4 2026, with accelerated approval potential

Item 7.01: Regulation FD Disclosure

  • PTC completed acquisition of ST-920 from Sangamo Therapeutics
  • ST-920 is a BLA-stage, one-time AAV gene therapy candidate for Fabry disease

AI summaries of PTCT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for PTCT

Don't miss the next PTCT filing

  • Alerts as it files. A push when PTCT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut PTCT, by share count.
  • Ask anything. An AI agent that reads every PTCT filing and answers with sources.

PTCT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Boulding Mark ElliottSellNov 16, 2026$62.90
Boulding Mark ElliottMNov 16, 2026$25.69
Boulding Mark ElliottSellNov 16, 2026$62.22
Boulding Mark ElliottMNov 16, 2026-
Boulding Mark ElliottSellNov 16, 2026$61.39
SCHMERTZLER MICHAELSellOct 14, 2026$59.52
SCHMERTZLER MICHAELSellOct 14, 2026$60.14
Boulding Mark ElliottMOct 9, 2026$39.42

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$806.8M$1.7B
Operating Income--$302.6M$866.9M
Net Income-$626.6M-$363.3M$682.6M
Op. Margin--37.5%50.1%
Net Margin--45.0%39.4%
Balance Sheet
Total Assets$1.9B$1.7B$2.9B
Equity--$1.1B-$205.3M
ROE-33.1%-332.5%
Per Share
EPS$-8.37$-4.73$7.78
Cash Flow
Operating CF--$107.7M$711.2M
CapEx$28.4M$6.5M$8.9M

Source: XBRL data in PTC THERAPEUTICS, INC. (PTCT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate PTCT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
PTCT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202634$2.64B
Q2 202634$3.45B
Q1 202634$2.70B
Q4 202531$2.96B
Q3 202531$2.10B
Q2 202529$1.69B
Q1 202526$1.18B
Q4 202423$889.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 242 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

PTCT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
8-KNov 3, 2026Analysis-
10-QOct 29, 2026Analysis
8-KOct 29, 2026Analysis-
4Oct 16, 2026--
4Oct 13, 2026--
4Oct 9, 2026--
4Oct 7, 2026--
4Oct 2, 2026--
8-KSep 21, 2026Analysis-
4Sep 18, 2026--
4Sep 11, 2026--
4Aug 28, 2026--
8-KAug 28, 2026Analysis-
4Aug 21, 2026--
4Aug 19, 2026--
8-KAug 13, 2026Analysis-
4Aug 6, 2026--
4Jul 30, 2026--
8-KJul 30, 2026Analysis-
10-QJul 30, 2026Analysis
4Jul 16, 2026--
4Jul 13, 2026--
4Jul 13, 2026--
4Jul 8, 2026--

Related Health Care companies

All Health Care →

PTCT SEC filings: frequently asked questions

Are PTCT insiders buying or selling?

In the last 90 days, PTC THERAPEUTICS, INC. (PTCT) officers, directors and 10% owners reported no open-market purchases and 22 open-market sales worth $5.9 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold PTCT stock?

As of September 30, 2026, the largest PTC THERAPEUTICS, INC. (PTCT) holders among the 13F filers tracked by SignalX were BlackRock ($932.7 million), State Street Corp ($357.1 million), Vanguard Portfolio Management LLC ($322.5 million), Vanguard Capital Management LLC ($234.4 million), Goldman Sachs Group ($105.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was PTCT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), PTC THERAPEUTICS, INC. (PTCT) reported revenue of $1.7 billion (up 114.5% from FY2024) and net income of $682.6 million. Diluted EPS was $7.78. The figures come from the XBRL data in the 10-K.

What are the main risks in PTCT's latest 10-K?

In the 10-K filed February 19, 2026, PTC THERAPEUTICS, INC. (PTCT) flagged: Regulatory risk U.S. FDA withdrawal of Translarna NDA resubmission for nmDMD after negative feedback in January 2026. Geopolitical exposure Sephience marketing approvals in U.S., EEA, Japan, Brazil with $111.2M 2025 net revenues, but country-specific pricing/licensing risks. (AI summary of the Risk Factors section.)

What did PTCT report in its latest 8-K?

PTC THERAPEUTICS, INC. (PTCT) filed an 8-K on November 3, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). Board-authorized share repurchase program announced November 3, 2026.

What are the latest PTCT SEC filings?

PTC THERAPEUTICS, INC. (PTCT) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on November 18, 2026.

What is PTCT's SEC CIK number?

PTC THERAPEUTICS, INC. (PTCT)'s SEC Central Index Key (CIK) is 1070081. EDGAR lists every PTCT filing under that number.

Ask anything about PTCT

The research agent reads PTCT's filings, financials, insider trades and 13F holders, then answers with sources.